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Some errors have been noted in the above-mentioned paper subsequent to publication and so the following corrections should be highlighted.

On page 1091 under the heading ***Treatment Patterns***, the sentence "Overall, the mean duration of treatment was 152.6 days, and there were no major differences between the two treatment groups, including the duration of add-on HCTZ treatment" should read "Overall, the mean duration of treatment was 151.2 days, and there were no major differences between the two treatment groups, including the duration of add-on HCTZ treatment." It should be clarified that 152.6 days was the mean duration of the double-blind treatment phase.

On page 1092 in ***Fig. 3***, the *p* value for the FAS group should read *p* = 0.0005, and not *p* \< 0.0001.

On page 1095 under the heading ***Safety/Tolerability***, the sentence "The most common adverse event was peripheral edema, which was reported in 17.8% of OLM/AML patients and 18.1% of PER/AML recipients" should read "The most common adverse event was peripheral edema, which was reported in 18.4% of OLM/AML patients and 17.8% of PER/AML recipients."

On page 1095 in ***Table 2***, the values in the row showing the frequencies of peripheral edema which are currently: 43 (17.8) in the OLM/AML column, 88 (18.1) in the PER/AML column, and 45 (18.4) in the total column; should read: 45 (18.4), 43 (17.8), and 88 (18.1), respectively.

The online version of the original article can be found under doi:10.1007/s12325-013-0076-6.
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